Infectious Diseases in Critical Care Medicine

37. Gotoh S, Nishimura T, Takahashi O, et al. Adrenal function in patients with community-acquired
    pneumonia. Eur Respir J. 2008; 31:1268–1273.


38. Jong GM, Hsiue TR, Chen CR, et al. Rapidly fatal outcome of bacteremicKlebsiellapneumonia in
    alcoholics. Chest 1995; 107:214–217.


39. Hohenthal U, Vainionpaa R, Meurman O, et al. Etiological diagnosis of community acquired
    pneumonia: utility of rapid microbiological methods with respect to disease severity. Scand J Infect
    Dis 2008; 40:131–138.


40. Bruns AH, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in
    adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007; 45:983–991.


41. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750-mg for 5 days for the treatment of
    hospitalized fine risk class III/IV community-acquired pneumonia patients. Respir Med 2006;
    100:2129–2136.


42. Cunha BA. Empiric therapy of community-acquired pneumonia. Chest 2004; 125:1913–1919.


43. Cunha BA. Clinical relevance of penicillin resistant Streptococcus pneumoniae. Semin Respir Infect
    Dis 2002; 17:204–214.


44. Cunha BA. Empiric antibiotic therapy for community-acquired pneumonia: guidelines for the
    perplexed? Chest 2004; 125:1913–1921.


45. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized
    patients. Clin Infect Dis 2004; 38:328–340.


46. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral
    antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006;
    333:1193.


47. Cunha BA. Oral and IV-to-PO switch antibiotic therapy of hospitalized patients with serious
    infections. Scand J Infect 2008; 40:1004–1006.


48. Cunha BA. Oral antibiotic therapy of serious systemic infections. Med Clin North Am 2006; 90:
    1197–2222.


49. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to
    Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis 2006; 12:894–899.


50. Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus
    aureus community-acquired pneumonia associated with influenza—Louisiana and Georgia, Decem-
    ber 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325–329.


51. Magira EE, Zervakis D, Routsi C, et al. Community-acquired methicillin-resistant Staphylococcus
    aureus carrying Panton-Valentine leukocidin genes: a lethal cause of pneumonia in an adult
    immunocompetent patient. Scand J Infect Dis 2007; 39:466–469.


52. Vayalumkal JV, Whittingham H, Vanderkooi O, et al. Necrotizing pneumonia and septic shock:
    suspecting CA-MRSA in patients presenting to Canadian emergency departments. CJEM 2007; 9:
    300–303.


53. Martino JL, McMillian WD, Polish LB, et al. Community-acquired methicillin-resistant Staphylococ-
    cus aureus pneumonia. Respir Med 2008; 102:932–934.


54. Mohan SS, McDermott BP, Cunha BA. Diagnostic and prognostic significance of relative lymphopenia
    in adult patients with influenza A. Am J Med 2005; 118:1307–1309.


55. Cunha BA. Amantadine may be lifesaving in severe influenza A. Clin Infect Dis 2006; 43:1574–1575.


56. Cunha BA. The clinical diagnosis of severe viral influenza A. Infection 2008; 36:92–93.


57. Saner FH, Heuer M, Rath PM, et al. Successful salvage therapy with tigecycline after linezolid failure
    in a liver transplant recipient with MRSA pneumonia. Liver Transpl 2006; 12:1689–1692.


58. Shakil S, Akram M, Khan AU. Tigecycline: a critical update. J Chemother 2008; 20:411–419.


59. Heath CH, Grove DI, Looke DF. Delay in appropriate therapy ofLegionellapneumonia associated with
    increased mortality. Eur J Clin Microbiol Infect Dis 1996; 5:286–290.


60. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in Adults and Children–Diagnosis,
    Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines
    of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1003–1032.


61. Hayden FG, Palese P. Influenza Virus. In: Clinical Virology (3rd ed.) Richman DD, Whitley RJ,
    Hayden FG (Eds). ASM Press, Washington, D.C. 2009, pp. 943–976.


62. Thomas JK, Noppenberger J. Avian influenza: a review. Am J Health System Pharm. 2007;64:149–165.


63. Uyeki TM. Human Infection with Highly Pathogenic Avian Influenza A (H5N1) Virus: Review of
    Clinical Issues. Clin Infect Dis. 2009;49;279–290.


64. Hien ND, Ha NH, Van NT, et al. Human Infection with Highly Pathogenic Avian Influenza Virus
    (H5N1) in Northern Vietnam, 2004–2005. Emerg Infect Dis 2009;15:19–23.


65. Centers for Disease Control and Prevention (CDC). Outbreak of swine-origin influenza A (H1N1)
    virus infection—Mexico, March-April 2009. Morb Mortal Wkly Rep. 2009;58:467–470.

Severe Community-Acquired Pneumonia in Critical Care 177